Navigation Links
Signum Biosciences, Inc. Announces Collaborative Agreement with GlaxoSmithKline
Date:11/10/2011

PRINCETON, N.J., Nov. 10, 2011 /PRNewswire/ -- Signum Biosciences, Inc., a privately held biotechnology company, has entered into an agreement with GlaxoSmithKline (China) R&D Company Limited (GSK) to collaborate on Signum's phosphatase screening technology and Phosphoprotein Phosphatase 2A (PP2A).

The agreement provides Signum with research support and milestone payments.  GSK receives the exclusive right of Signum's proprietary phosphatase screening technology for GSK's research and development activities in neurosciences.

GSK and Signum will undertake a broad R&D collaboration to screen and identify PP2A targeted compounds including those bridging the link between PP2A methylation and tau hyperphosphorylation.  Signum's partnership with GSK furthers Signum's position as an innovative biotech company, advancing pioneering drug discovery and leveraging GSK's capabilities in research and development.

Maxwell Stock, President of Signum Biosciences, commented, "GSK is an ideal partner for Signum.  We will develop therapeutics using our phosphatase screening technology in an alliance that utilizes the expertise of both companies.  We are proud to be working in collaboration with a leading pharmaceutical company in innovative research and development.  Collaborations such as these allow partners to share knowledge, expertise and resources and thereby provide a highly effective way of progressing cutting edge research and developing an effective drug."  

About Signum Biosciences, Inc.

Signum, a Princeton, New Jersey- based biotechnology company, dedicated to developing small-molecule therapeutics derived from its Phosphatase platform to modulate signal transduction imbalances.  Through research on protein networks that control biological systems, Signum is developing therapeutic agents for Alzheimer's, Parkinson's and other neurodegenerative diseases.  Signum's technology provid
'/>"/>

SOURCE Signum Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics
2. Signum Biosciences, Inc. Announces Commercial Launch of Arazineā„¢
3. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
4. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
5. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
6. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
7. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
8. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
9. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
11. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
(Date:8/29/2014)... -- Diseases largely eradicated in the United ... was declared eliminated in 2000, yet the CDC reports ... highest incidence in 20 years. In July, ... a problem of "epidemic proportions." ... these preventable diseases—in part because some parents (more than ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Global Multiple Sclerosis Drugs Market 2014-2018" ... is a chronic, inflammatory medical condition that results in ... damaged because of an abnormal response by the immune ... (CNS). It is a potentially debilitating disease in which ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Ala., Dec. 14 BioCryst,Pharmaceuticals, Inc. (Nasdaq: ... data evaluating forodesine HCl, the Company,s lead anti-cancer,compound, ... and lymphomas., Madeline Duvic, M.D., Deputy Chair, ... presented interim data from the Phase,I/II clinical study ...
... the Treatment of PKU, NOVATO, Calif., Dec. ... announced today that the U.S.,Food and Drug Administration ... Tablets, the first specific drug,therapy approved for the ... will commence tomorrow, and BioMarin will begin,promotion of ...
Cached Medicine Technology:Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma 2Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma 3Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma 4BioMarin Announces FDA Approval for Kuvan 2BioMarin Announces FDA Approval for Kuvan 3BioMarin Announces FDA Approval for Kuvan 4BioMarin Announces FDA Approval for Kuvan 5BioMarin Announces FDA Approval for Kuvan 6BioMarin Announces FDA Approval for Kuvan 7BioMarin Announces FDA Approval for Kuvan 8
(Date:8/29/2014)... a systematic review of clinical trials based on ... researchers have concluded that more trials are needed ... for postsurgical pain on a regular basis., Dr. ... pain research in the Department of Anesthesiology, and ... to determine whether the use of antidepressants for ...
(Date:8/29/2014)... Colo. (Sept. 2, 2014) A team of scientists ... reported the breakthrough discovery of a process to expand ... These findings could have implications that extend beyond cancer, ... autoimmune diseases., In an article published Aug. ... Charles C. Gates Center for Regenerative Medicine and Stem ...
(Date:8/29/2014)... Mass. (August 29, 2014, 2 PM US Eastern ... is to inject antibodies, commonly produced in animals, ... challenges ranging from safety to difficulties in developing, ... , New research led by Charles Shoemaker, ... and Global Health at the Cummings School of ...
(Date:8/29/2014)... EDMONTON, AB A new study from the research group ... AB) and the Lawson Health Research Institute (London, ON) has ... of cancer. The study, published in Cell Reports , ... spread of cancer entirely. , Roughly 2 in 5 ... four of them will die of the disease. In 2014, ...
(Date:8/29/2014)... Francisco, CA (PRWEB) August 30, 2014 ... 10 best web conference providers in the online service ... the list were global leaders Webex, GotoMeeting and Infinite. ... the industry users have to determine which provider is ... Essentially, web conference businesses search for compelling consumer goods ...
Breaking Medicine News(10 mins):Health News:Antidepressants show potential for postoperative pain 2Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:Mice study shows efficacy of new gene therapy approach for toxin exposures 2Health News:Preventing cancer from forming 'tentacles' stops dangerous spread 2Health News:Top10InAction Reveals Best Web Conference Providers 2
... WASHINGTON, Sept. 2 Speaker Nancy Pelosi and Senate Majority Leader Harry Reid ... Session of Congress on Wednesday, September 9, 2009. , , ... , September 2, 2009 , , President Barack ... Dear Mr. President: , , Our nation is closer than ever ...
... ATLANTA, Sept. 2 /PRNewswire-FirstCall/ -- Gentiva Health Services, Inc. ... health services, announced today that it has completed its acquisition of ... the Rush Health System, located in central Mississippi and west central ... , "We extend a warm welcome to all ...
... , , WASHINGTON, Sept. ... President, Campaign for Tobacco-Free Kids: , , (Logo: ... have taken decisive action to protect the state,s kids and taxpayers from ... by $1 to $3.00 per pack, making it the second highest state ...
... Study found more than half of advanced basal cell carcinomas ... -- An experimental cancer drug that switches off the so-called ... patients with advanced basal cell carcinoma, a type of skin ... from medulloblastoma, the most common form of brain cancer in ...
... , OAKLAND, Calif., Sept. 2 Wigix ( ... database on the web. Wigix has surpassed Overstock.com and ... (Source: Internet Retailers Top 500 Guide 2009 Edition) , , ... thousand SKUs during its public beta launch in June 2007. This milestone marks ...
... , , , ... the House Democrat healthcare bill (H.R. 3200) that violate President Obama,s promise ... $250,000 per year. The White House has told reporters that Obama ... week, which begs the question: , , ...
Cached Medicine News:Health News:Gentiva(R) Health Services Completes Acquisition of Home Health Agency 2Health News:Gentiva(R) Health Services Completes Acquisition of Home Health Agency 3Health News:Connecticut Cigarette Tax Increase Delivers Victory for Kids and Taxpayers; $1 Increase Gives State Second Highest Cigarette Tax in the Nation 2Health News:Connecticut Cigarette Tax Increase Delivers Victory for Kids and Taxpayers; $1 Increase Gives State Second Highest Cigarette Tax in the Nation 3Health News:New Compound Shrinks Skin Cancers 2Health News:New Compound Shrinks Skin Cancers 3Health News:New Compound Shrinks Skin Cancers 4Health News:Wigix Announces 1 Million in Open Sell Orders 2Health News:Obama's 'Specific' Healthcare Speech: Will He Disavow Pledge-Breaking Tax Hikes in House Dem Health Bill? 2
Stainless steel construction to withstand sterilization modalities (EtO) Wide angle of view...
Inquire...
ENDOlap™ laparoscopes provide excellent image linearity and flatness of field....
The Fujinon's R410 laparoscope is the first to bring a 410,000 pixel CCD to the end of the scope. Superior imaging and color replication, along with a unique lens washing capability make the R410 the...
Medicine Products: